Biggest drop was N4P:N4 Pharma which fell a massive 17% despite news that trials of their Viagra replacement Sildenafil are about to begin. They were in profit last week but now down 12% which is rather frustrating.
IQE:IQE fell by 13% as the shorters take control. Maybe I should have kept the cash from the shares I sold to buy back once they get clobbered. Instead I'll have to watch my remaining SIPP holding plunge to a big loss like the rest of my shares.
OPTI:Optibiotix released yet more good news but the effect was the same as usual as it fell 5%. That's 3p and so contributed to £1,900 of this week's loss.
My favourite yo-yo share CAML:Central Asia Metals had a down week this week, falling 6%. I thought there would be a rise as people buy in for the dividend, but no.
Although the general sentiment was gloomy this week, there were a few good news stories. MTFB:Motif Bio are gradually sneaking up now the NDA is being incrementally submitted. They rose 6% this week and are now 10% up, which gives me paper profit of £316 with my enlarged holding.
A holding RNS revealed Woodford has increased holdings by 1% in TRX:Tissue Regenix which explains the recent recovery. Up 7% this week but still 48% down on purchase price.
Share of the Week is SBTX:SkinBioTherapeutics which zoomed up 15%. Is there danger this could finally get back into profit before my free shares arrive? They are only 19% down on purchase price now.
The recovery didn't last very long, and the gap is now wider than ever.
Here's the ISA and share accounts performance
| Weekly Change | |||
| Cash | £10.86 | +£4.25 | |
| Portfolio cost | £51,874.49 | +£1,764.84 | |
| Portfolio sell value (bid price - commission) | £41.532.74 | (-19.9%) | -£3,093.26 |
| Potential profits | £334.56 | -£1,836.59 | |
| Yr 3 Dividends | £44.15 | +£0 | |
| Yr 3 Profit from sales | £8,033.77 | +£1,786.99 | |
| Yr 3 Average monthly cash profit | £942.55 | (21.8%) | +£188.92 |
| Total Dividends | £1,223.20 | +£0 | |
| Total Profit from sales | £14,746.27 | +£1,786.99 | |
| Average monthly cash profit | £486.63 | (11.3%) | +£51.84 |
| (Sold stocks profit + Dividends - Fees / Months) |
Cost increased as the IQE:IQE profits were re-invested and accounted for nearly all the drop in potential profits. The rest of the portfolio lost around £1,200 much of which was OPTI:Optibiotix. The effect of the sale on average monthly profit was amazing, passing 11% and giving me plenty of time above my 10% target before having to make another sale.
As with the combined chart, this looks dreadful
Here's the SIPP after week 125
| Weekly Change | |||
| Cash | £19.97 | +£0 | |
| Portfolio cost | £27,016.24 | +£0 | |
| Portfolio sell value (bid price - commission) | £26,454.19 | (-2.1%) | -£1,314.64 |
| Potential profits | £3,487.24 | -£257.00 | |
| Yr 3 Dividends | £0 | +£0 | |
| Yr 3 Profit from sales | £1,023.84 | +£0 | |
| Yr 3 Average monthly cash profit | £200.65 | (8.9%) | -£10.03 |
| Total Dividends | £916.10 | +£0 | |
| Total Profit from sales | £9,949.03 | +£0 | |
| Average monthly cash profit | £369.75 | (16.4%) | -£2.98 |
| (Sold stocks profit + Dividends - Fees / Months) |
General misery as unlike last week when everything went up, this week everything except TRX:Tissue Regenix was down.
Back in the red after a fleeting week in the black.
Here's the trading account after week 91
| Weekly Change | |||
| Cash | £0.03 | +£0 | |
| Portfolio cost | £345.65 | +£0 | |
| Portfolio sell value (bid price - commission) | £206.08 | (-40.2%) | -£2.98 |
| Potential profits | £0 | +£0 | |
| Year 2 Dividends | £0 | +£0 | |
| Year 2 Profit | -£218.50 | +£0 | |
| Yr 2 Average monthly cash profit | -£24.28 | (-84.3%) | +£0.64 |
| Dividends | £1.15 | +£0 | |
| Profit from sales | -£241.35 | +£0 | |
| Average monthly cash profit | -£11.44 | (-39.7%) | +£0.13 |
| (Sold stocks profit + Dividends - Fees / Months) |
Hardly any change in LION:Lionsgold this week, and possible news of the Railsbank takeover next week.
There's still hope!
Although it's been a miserable week, it could have been worse. I was looking at IMM:Immupharma at the same time I was looking at N4P:N4 Pharma but gave them a miss as it seemed a shit or bust strategy compared to N4P:N4 Pharma with a more diverse portfolio. Unfortunately for shareholders it was a bust, as the share price collapsed following disappointing trial results. At least this week's losses were relatively small for my portfolio and could bounce back quite quickly.
I've used up all my ammo selling IQE:IQE so have no more wiggle room for other purchases. I'm really happy with the shares I bought using my IQE:IQE profits, but have to accept they are all pre-revenue and high risk. All I can do now is sit back and wait, and hope I made the right decisions.
No comments:
Post a Comment